Latest On Caladrius Biosciences, Inc (CLBS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-09-14 20:16 EST | News | Caladrius rallies on approval of merger, name change to Lisata Therapeutics | N/A |  |
| 2022-08-10 14:14 EST | News | Cend, Roche team up for trial of CEND-1/Tecentriq in pancreatic cancer | N/A | |
| 2022-08-05 00:52 EST | News | Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01 | N/A | |
| 2022-08-05 00:51 EST | News | Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-03 18:45 EST | News | Caladrius Biosciences Q2 2022 Earnings Preview | N/A | |
| 2022-05-24 15:58 EST | News | Caladrius suspends enrollment in mid-stage study for heart disease candidate | N/A | |
| 2022-05-06 22:41 EST | News | Caladrius Biosciences, Inc. 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-06 00:48 EST | News | Caladrius Biosciences GAAP EPS of -$0.07 | N/A | |
| 2022-05-06 00:47 EST | News | Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-05 01:14 EST | News | Caladrius Biosciences Q1 2022 Earnings Preview | N/A | |
| 2022-04-27 20:06 EST | News | Caladrius Biosciences to merge with Cend Therapeutics | N/A | |
| 2022-04-13 01:00 EST | News | Caladrius treats 1st patient in phase 1b trial of cell therapy CLBS201 for diabetic kidney disease | N/A | |
| 2022-03-24 07:02 EST | News | Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-22 20:48 EST | News | Caladrius Biosciences Q4 2021 Earnings Preview | N/A | |
| 2022-03-22 20:47 EST | News | Caladrius Biosciences GAAP EPS of -$0.11 | N/A | |
| 2021-11-05 03:11 EST | News | Caladrius Biosciences EPS beats by $0.01 | N/A | |
| 2021-11-05 03:11 EST | News | Caladrius Biosciences Inc.'s (CLBS) CEO David Mazzo on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-04 06:02 EST | News | Caladrius Biosciences Q3 2021 Earnings Preview | N/A | |
| 2021-08-17 10:51 EST | News | Caladrius Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-08-06 00:09 EST | News | Caladrius Biosciences EPS beats by $0.04 | N/A | |
| 2021-08-06 00:08 EST | News | Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-21 00:31 EST | News | Caladrius Bio to assess CLBS201 in diabetic kidney disease | N/A | |
| 2021-05-07 05:43 EST | News | Caladrius Biosciences EPS misses by $0.10 | N/A | |
| 2021-05-07 05:42 EST | News | Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2021-04-02 08:34 EST | News | Caladrius Biosciences files for $150M mixed shelf offering. | N/A | |
| 2021-03-16 21:35 EST | News | Checking In On Caladrius Biosciences | N/A | |
| 2021-03-16 20:28 EST | Analyst Rating | The Analyst Target Price has increased from $8.67 to $10. | Buy | |
| 2021-03-08 23:24 EST | Analyst Rating | The Analyst Target Price has decreased from $10 to $8.67. | Neutral | |
| 2021-03-04 15:20 EST | Analyst Rating | The Analyst Target Price has increased from $9 to $10. | Buy | |
| 2021-03-01 15:18 EST | Earnings Estimate | An EPS average of -$0.08 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-01 15:18 EST | Earnings Estimate | An EPS average of -$0.41 is estimated for the 2022 year. | Sell | |
| 2021-02-28 16:55 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-26 16:59 EST | News | Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-25 22:25 EST | News | Caladrius Biosciences EPS misses by $0.02 | N/A | |
| 2021-02-12 16:17 EST | News | Caladrius Biosciences shares slide 20% on capital raise | N/A | |
| 2021-01-21 22:25 EST | News | Caladrius under pressure on $25M capital raise | N/A | |
| 2021-01-21 11:24 EST | Analyst Rating | The Analyst Target Price has increased from $6.5 to $9. | Buy | |
| 2021-01-20 15:56 EST | News | NFLX, TELL, CLBS, and FUTU among notable pre-market gainers | N/A | |
| 2021-01-20 01:27 EST | News | Caladrius initiates mid-stage study with CLBS16 in heart disease | N/A | |
| 2020-12-25 15:20 EST | Analyst Rating | The Analyst Target Price has decreased from $7 to $6.5. | Neutral | |
| 2020-12-24 23:32 EST | Analyst Rating | The Analyst Target Price has increased from $6.5 to $7. | Buy | |
| 2020-12-14 16:33 EST | News | Caladrius suspends CLBS119 COVID-19 study | N/A | |
| 2020-12-13 03:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 11:25 EST | Analyst Rating | The Analyst Target Price has decreased from $10.5 to $6.5. | Neutral | |
| 2020-11-10 03:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 15:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 11:24 EST | Earnings Estimate | An EPS average of -$0.27 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-06 04:47 EST | News | Caladrius Biosciences EPS misses by $0.06 | N/A | |
| 2020-11-06 04:46 EST | News | Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-03 19:18 EST | Insider Trade | Anne Clem Whitaker has directly acquired 79,470 shares and currently holds 79,470 shares. | Buy | |
About Caladrius Biosciences, Inc (CLBS):
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
General
- Name Caladrius Biosciences, Inc
- Symbol CLBS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 24
- Last Split Factor1:10
- Last Split Date2016-07-28
- Fiscal Year EndDecember
- IPO Date1999-03-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.caladrius.com
View More
Valuation
- Price/Book (Most Recent Quarter) 3.52
- Enterprise Value EBITDA 0.47
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.51
- Next Year EPS Estimate -$0.32
- Next Quarter EPS Estimate -$0.08
- Return on Assets -38%
- Return on Equity -31%
- Earnings Per Share -$1.87
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 119.61 million
- Analyst Target Price $10
- Book Value Per Share $1.68
View More
Share Statistics
- Shares Outstanding 59.51 million
- Shares Float 46.06 million
- % Held by Insiders 1218%
- % Held by Institutions 19.23%
- Shares Short 471217
- Shares Short Prior Month 1.45 million
- Short Ratio 0.06
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 1.22
- 52 Week High $3.21
- 52 Week Low $1.25
- 50 Day Moving Average 2.12
- 200 Day Moving Average 1.79
View More
Dividends
- Dividend Date 2016-07-28
- ExDividend Date N/A
- Dividend Yield 0%
View More
Caladrius Biosciences, Inc (CLBS) Dividend Calendar:
CLBS's last dividend payment was made to shareholders on July 28, 2016.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Caladrius Biosciences, Inc (CLBS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $N/A | -$0.28 | -$0.26 | -7.69% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.29 | -$0.23 | -28.89% |
| 2020-06-30 | 2020-08-13 | $N/A | $0.50 | -$0.37 | 235.14% |
| 2020-03-31 | 2020-05-08 | $N/A | -$0.38 | -$0.44 | 13.64% |
| 2019-12-31 | 2020-03-05 | $N/A | -$0.47 | -$0.44 | -6.82% |
| 2019-09-30 | 2019-11-06 | $N/A | -$0.47 | -$0.43 | -9.3% |
| 2019-06-30 | 2019-08-08 | $N/A | -$0.49 | -$0.45 | -10.11% |
| 2019-03-31 | 2019-05-09 | $N/A | -$0.44 | -$0.43 | -3.53% |
| 2018-12-31 | 2019-03-14 | $N/A | -$0.36 | -$0.44 | 18.18% |
| 2018-09-30 | 2018-11-08 | $N/A | -$0.36 | -$0.54 | 33.33% |
| 2018-06-30 | 2018-08-09 | $N/A | -$0.42 | -$0.64 | 34.38% |
| 2018-03-31 | 2018-05-10 | $N/A | -$0.52 | -$0.67 | 22.39% |
| 2017-12-31 | 2018-03-22 | $N/A | -$0.74 | -$0.78 | 4.58% |
| 2017-09-30 | 2017-11-09 | $7.92 million | -$0.38 | -$0.78 | 50.97% |
| 2017-06-30 | 2017-08-10 | $-15845334 | -$0.22 | -$0.96 | 77.08% |
| 2017-03-31 | 2017-05-15 | $7.92 million | -$1.12 | -$0.72 | -54.99% |
| 2016-12-31 | 2017-03-17 | $10.18 million | -$0.54 | -$0.80 | 32.08% |
| 2016-09-30 | 2016-11-07 | $9.32 million | -$1.09 | -$1.51 | 27.69% |
| 2016-06-30 | 2016-08-09 | $8.3 million | -$1.33 | -$1.75 | 24% |
| 2016-03-31 | 2016-05-05 | $7.49 million | -$2.10 | -$0.80 | -162.5% |
| 2015-12-31 | 2016-03-15 | $7.56 million | $0.77 | -$2.93 | 126.25% |
| 2015-09-30 | 2015-11-05 | $5.89 million | -$2.10 | -$3.43 | 38.78% |
| 2015-06-30 | 2015-08-06 | $5.87 million | -$3.80 | -$3.08 | -23.38% |
| 2015-03-31 | 2015-05-05 | $3.17 million | -$5.10 | -$3.60 | -41.67% |
| 2014-12-31 | 2015-03-02 | $5.28 million | -$3.20 | -$4.18 | 23.45% |
| 2014-09-30 | 2014-10-30 | $4.12 million | -$4.80 | -$3.42 | -40.35% |
| 2014-06-30 | 2014-08-07 | $4.49 million | -$4.00 | -$2.98 | -34.23% |
| 2014-03-31 | 2014-05-08 | $4.06 million | -$4.90 | -$3.95 | -24.05% |
| 2013-12-31 | 2014-03-13 | $4.08 million | -$4.70 | -$3.57 | -31.65% |
| 2013-09-30 | 2013-11-07 | $3.71 million | -$4.50 | -$4.22 | -6.64% |
| 2013-06-30 | 2013-08-08 | $4.36 million | -$4.60 | -$4.10 | -12.2% |
| 2013-03-31 | 2013-05-09 | $2.52 million | -$5.00 | -$4.50 | -11.11% |
| 2012-12-31 | 2013-03-11 | $-15532937 | -$10.00 | -$5.33 | -87.62% |
| 2012-09-30 | 2012-11-14 | $4.43 million | -$6.00 | -$5.00 | -20% |
| 2012-06-30 | 2012-08-14 | $3.37 million | -$5.00 | -$8.00 | 37.5% |
| 2012-03-31 | 2012-05-11 | $22.06 million | -$8.00 | -$8.00 | 0% |
| 2011-12-31 | 2012-03-20 | $4.21 million | -$19.00 | -$6.75 | -181.48% |
| 2011-09-30 | 2011-11-11 | $17.76 million | -$8.00 | -$11.00 | 27.27% |
| 2011-06-30 | 2011-08-12 | $18.46 million | -$13.00 | -$9.40 | -38.3% |
| 2011-03-31 | 2011-04-01 | $1.45 million | -$10.00 | -$8.17 | -22.4% |
| 2010-12-31 | 2011-03-31 | $18.11 million | -$10.00 | -$8.17 | -22.4% |
| 2010-09-30 | 2010-11-12 | $16.48 million | -$13.00 | -$8.00 | -62.5% |
| 2010-06-30 | 2010-08-16 | $19.41 million | -$11.00 | -$6.33 | -73.78% |
| 2010-03-31 | 2010-05-17 | $15.83 million | -$12.00 | -$5.00 | -140% |
| 2009-12-31 | 2010-03-03 | $11.41 million | -$126.36 | ||
| 2009-09-30 | 2009-12-02 | $85000 | -$89.57 | ||
| 2009-06-30 | 2009-06-30 | $28000 | -$62.02 | ||
| 2009-03-31 | 2009-03-31 | $45000 | -$23.93 | ||
| 2008-12-31 | 2008-12-31 | $35000 | -$31.00 | ||
| 2008-09-30 | 2008-09-30 | $25000 | -$30.11 | ||
| 2008-06-30 | 2008-06-30 | $23000 | -$43.02 | ||
| 2008-03-31 | 2008-03-31 | $1000 | -$51.53 | ||
| 2007-12-31 | 2007-12-31 | $158000 | -$71.35 | ||
| 2007-09-30 | 2007-09-30 | $12000 | -$125.79 | ||
| 2007-06-30 | 2007-06-30 | $6000 | -$737.00 | ||
| 2007-03-31 | 2007-03-31 | $56000 | -$73.49 | ||
| 2006-09-30 | 2006-09-30 | $6000 | -$109.18 | ||
| 2006-06-30 | 2006-06-30 | $7000 | -$123.10 | ||
| 2006-03-31 | 2006-03-31 | $6000 | -$150.76 | ||
| 2005-12-31 | 2005-12-31 | $7000 | -$105.87 | ||
| 2005-09-30 | 2005-09-30 | $8000 | -$112.29 | ||
| 2005-06-30 | 2005-06-30 | $9000 | -$90.06 | ||
| 2005-03-31 | 2005-03-31 | $11000 | -$59.55 | ||
| 2004-09-30 | 2004-09-30 | $3000 | -$149.56 | ||
| 2004-06-30 | 2004-06-30 | $7000 | -$166.83 | ||
| 2004-03-31 | 2004-03-31 | $27000 | -$171.18 | ||
| 2003-12-31 | 2003-12-31 | $15000 | -$200.00 | ||
| 2003-09-30 | 2003-09-30 | $15000 | -$93.09 | ||
| 2003-06-30 | 2003-06-30 | $17000 | -$114.84 | ||
| 2003-03-31 | 2003-03-31 | $18000 | -$68.79 | ||
| 2002-09-30 | 2002-09-30 | $20000 | -$103.13 | ||
| 2002-06-30 | 2002-06-30 | $18000 | -$110.56 | ||
| 2002-03-31 | 2002-03-31 | $25000 | -$153.32 | ||
| 2001-09-30 | 2001-09-30 | $33000 | -$167.79 | ||
| 2001-03-31 | 2001-03-31 | $11000 | $94.68 | ||
| 2000-09-30 | 2000-09-30 | $-35000 | -$679.03 | ||
| 2000-06-30 | 2000-06-30 | $35000 | -$268.80 | ||
| 2000-03-31 | 2000-03-31 | $1000 | -$148.30 | ||
| 1999-09-30 | 1999-09-30 | -$636.42 | |||
| 1999-06-30 | 1999-06-30 | -$961.29 | |||
| 1999-03-31 | 1999-03-31 | -$642.20 | |||
| 1998-09-30 | 1998-09-30 | -$212.77 | |||
| 1998-06-30 | 1998-06-30 | -$231.93 |
Caladrius Biosciences, Inc (CLBS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 2.91 million | 3.03 million | N/A | 1.5 million | 2.77 million |
| Income Before Tax | -5.43 million | -5.33 million | N/A | -3.99 million | -4.95 million |
| Selling General Administrative | 2.54 million | 2.32 million | N/A | 2.56 million | 2.32 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -5.43 million | -5.33 million | N/A | -4.04 million | -5.08 million |
| Operating Income | -5.45 million | -5.35 million | N/A | -4.06 million | -5.08 million |
| Income Tax Expense | N/A | N/A | -10.87 million | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | 71000 | 129000 |
| Net Income From Continuing Operations | -5.43 million | -5.33 million | N/A | -3.99 million | -4.95 million |
| Net Income Applicable to Common Shares | -5.43 million | -5.33 million | 6.6 million | -3.99 million | -4.96 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -11.04 million | -8.25 million | N/A | 5.3 million | 5.38 million |
| Change to Liabilities | 605000 | -1.23 million | -1.44 million | -90000 | -39000 |
| Total Cash Flow from Investing Activities | -11.04 million | -8.25 million | 11.1 million | 5.3 million | 5.38 million |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | 9.03 million | 9.68 million | N/A | 275000 | N/A |
| Change to Operating Activities | N/A | -1.2 million | 587000 | 500000 | 171000 |
| Change in Cash | -5.53 million | 5.94 million | N/A | 1.36 million | 920000 |
| Total Cash from Operating Activities | -3.52 million | 4.5 million | -4.24 million | -4.22 million | -4.46 million |
| Depreciation | 16000 | 15000 | N/A | 15000 | 15000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 229000 | 319000 | 590000 | 302000 | 294000 |
| Capital Expenditures | N/A | 12000 | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 3.76 million | 4.53 million | 3.93 million | 5.16 million | 6.6 million |
| Total Stockholder Equity | 32.5 million | 37.74 million | 33.81 million | 17.24 million | 20.82 million |
| Other Current Liabilities | N/A | N/A | N/A | 914000 | N/A |
| Total Assets | 36 million | 42.02 million | 37.48 million | 22.14 million | 27.15 million |
| Common Stock | 19000 | 19000 | 16000 | 11000 | 11000 |
| Other Current Assets | 758000 | 989000 | N/A | N/A | N/A |
| Retained Earnings | -425.55 million | -420.12 million | -414.79 million | -421.39 million | -417.4 million |
| Other Liabilities | N/A | N/A | N/A | 536000 | 624000 |
| Other Assets | N/A | N/A | 41000 | 847000 | 1.08 million |
| Cash | 16.51 million | 21.16 million | 26.68 million | 20.75 million | 14.03 million |
| Total Current Liabilities | 3.51 million | 4.18 million | 3.48 million | 4.62 million | 5.98 million |
| Other Stockholder Equity | -13000 | -12000 | -7000 | N/A | 2000 |
| Property, Plant & Equipment | 57000 | 67000 | 814000 | 87000 | 100000 |
| Total Current Assets | 35.33 million | 41.26 million | 36.63 million | 21.21 million | 25.97 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 32.5 million | 37.74 million | 33.81 million | 17.24 million | 20.82 million |
| Short Term Investments | 18.06 million | 19.11 million | 8.21 million | N/A | 11.13 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 3.51 million | 1.11 million | 592000 | 64000 | 1.49 million |
Caladrius Biosciences, Inc (CLBS) Chart:
Caladrius Biosciences, Inc (CLBS) News:
Below you will find a list of latest news for Caladrius Biosciences, Inc (CLBS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Caladrius Biosciences, Inc (CLBS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest CLBS Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:54 PM EST | 500 | $0.51 |
| Jun 13, 2022 7:54 PM EST | 400 | $0.51 |
| Jun 13, 2022 7:54 PM EST | 93 | $0.51 |
| Jun 13, 2022 7:54 PM EST | 407 | $0.51 |
| Jun 13, 2022 7:54 PM EST | 400 | $0.51 |
Caladrius Biosciences, Inc (CLBS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000056/0000320017-20-000056-index.htm |
| 2018-07-31 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/320017/000000000018023614/0000000000-18-023614-index.htm |
| 2020-06-25 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/320017/000000000020005723/0000000000-20-005723-index.htm |
| 2020-08-25 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/320017/000000000020007973/0000000000-20-007973-index.htm |
| 2017-09-20 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/320017/000032001717000079/0000320017-17-000079-index.htm |
| 2017-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001717000082/0000320017-17-000082-index.htm |
| 2017-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001717000084/0000320017-17-000084-index.htm |
| 2017-11-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001717000093/0000320017-17-000093-index.htm |
| 2017-11-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001717000094/0000320017-17-000094-index.htm |
| 2018-01-04 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/320017/000032001718000004/0000320017-18-000004-index.htm |
| 2018-02-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001718000012/0000320017-18-000012-index.htm |
| 2018-02-08 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/320017/000032001718000013/0000320017-18-000013-index.htm |
| 2018-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001718000015/0000320017-18-000015-index.htm |
| 2018-03-22 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/320017/000032001718000021/0000320017-18-000021-index.htm |
| 2018-03-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001718000022/0000320017-18-000022-index.htm |
| 2018-04-02 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/320017/000032001718000025/0000320017-18-000025-index.htm |
| 2018-04-24 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/320017/000032001718000031/0000320017-18-000031-index.htm |
| 2018-04-24 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/320017/000032001718000032/0000320017-18-000032-index.htm |
| 2018-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001718000038/0000320017-18-000038-index.htm |
| 2018-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001718000039/0000320017-18-000039-index.htm |
| 2018-06-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001718000065/0000320017-18-000065-index.htm |
| 2018-06-20 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/320017/000032001718000067/0000320017-18-000067-index.htm |
| 2018-06-20 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/320017/000032001718000069/0000320017-18-000069-index.htm |
| 2018-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000032001718000074/0000320017-18-000074-index.htm |
| 2018-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000032001718000076/0000320017-18-000076-index.htm |
| 2018-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000032001718000078/0000320017-18-000078-index.htm |
| 2018-07-24 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/320017/000032001718000083/0000320017-18-000083-index.htm |
| 2018-07-31 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/320017/000032001718000087/0000320017-18-000087-index.htm |
| 2018-08-02 | 424B2 | Prospectus [Rule 424(b)(2)] | https://www.sec.gov/Archives/edgar/data/320017/000032001718000100/0000320017-18-000100-index.htm |
| 2018-08-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001718000102/0000320017-18-000102-index.htm |
| 2018-08-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/320017/000032001718000104/0000320017-18-000104-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001718000112/0000320017-18-000112-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001718000113/0000320017-18-000113-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001718000122/0000320017-18-000122-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001718000124/0000320017-18-000124-index.htm |
| 2019-01-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000004/0000320017-19-000004-index.htm |
| 2019-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000008/0000320017-19-000008-index.htm |
| 2019-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000020/0000320017-19-000020-index.htm |
| 2019-03-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/320017/000032001719000022/0000320017-19-000022-index.htm |
| 2019-03-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/320017/000032001719000024/0000320017-19-000024-index.htm |
| 2019-03-19 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/320017/000032001719000027/0000320017-19-000027-index.htm |
| 2019-03-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/320017/000032001719000032/0000320017-19-000032-index.htm |
| 2019-04-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000036/0000320017-19-000036-index.htm |
| 2019-04-11 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000039/0000320017-19-000039-index.htm |
| 2019-04-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/320017/000032001719000045/0000320017-19-000045-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001719000053/0000320017-19-000053-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000055/0000320017-19-000055-index.htm |
| 2019-06-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000060/0000320017-19-000060-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001719000069/0000320017-19-000069-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000071/0000320017-19-000071-index.htm |
| 2019-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001719000086/0000320017-19-000086-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000087/0000320017-19-000087-index.htm |
| 2019-11-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001719000091/0000320017-19-000091-index.htm |
| 2020-03-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000015/0000320017-20-000015-index.htm |
| 2020-03-05 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000016/0000320017-20-000016-index.htm |
| 2020-04-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000019/0000320017-20-000019-index.htm |
| 2020-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000022/0000320017-20-000022-index.htm |
| 2020-04-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000024/0000320017-20-000024-index.htm |
| 2020-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/320017/000032001720000028/0000320017-20-000028-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000035/0000320017-20-000035-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000036/0000320017-20-000036-index.htm |
| 2020-05-12 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/320017/000032001720000037/0000320017-20-000037-index.htm |
| 2020-05-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000039/0000320017-20-000039-index.htm |
| 2020-05-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000041/0000320017-20-000041-index.htm |
| 2020-06-05 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/320017/000032001720000042/0000320017-20-000042-index.htm |
| 2020-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000046/0000320017-20-000046-index.htm |
| 2020-06-19 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/320017/000032001720000050/0000320017-20-000050-index.htm |
| 2020-06-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/320017/000032001720000053/0000320017-20-000053-index.htm |
| 2020-06-30 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000056/0000320017-20-000056-index.htm |
| 2020-07-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000060/0000320017-20-000060-index.htm |
| 2020-07-27 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/320017/000032001720000061/0000320017-20-000061-index.htm |
| 2020-07-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000065/0000320017-20-000065-index.htm |
| 2020-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000073/0000320017-20-000073-index.htm |
| 2020-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000084/0000320017-20-000084-index.htm |
| 2020-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000085/0000320017-20-000085-index.htm |
| 2020-08-18 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/320017/000032001720000093/0000320017-20-000093-index.htm |
| 2020-08-18 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/320017/000032001720000094/0000320017-20-000094-index.htm |
| 2020-08-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/320017/000032001720000096/0000320017-20-000096-index.htm |
| 2020-09-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000099/0000320017-20-000099-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000032001720000109/0000320017-20-000109-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/320017/000032001720000110/0000320017-20-000110-index.htm |
| 2020-05-04 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/320017/000091957420003131/0000919574-20-003131-index.htm |
| 2019-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000107827419000006/0001078274-19-000006-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000107827419000009/0001078274-19-000009-index.htm |
| 2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000107827420000002/0001078274-20-000002-index.htm |
| 2020-11-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000110465920121060/0001104659-20-121060-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000110465920121061/0001104659-20-121061-index.htm |
| 2017-11-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420417055543/0001144204-17-055543-index.htm |
| 2018-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418001693/0001144204-18-001693-index.htm |
| 2018-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418001697/0001144204-18-001697-index.htm |
| 2018-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418001699/0001144204-18-001699-index.htm |
| 2018-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418001701/0001144204-18-001701-index.htm |
| 2018-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418001703/0001144204-18-001703-index.htm |
| 2018-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418001704/0001144204-18-001704-index.htm |
| 2018-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418001705/0001144204-18-001705-index.htm |
| 2018-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418020001/0001144204-18-020001-index.htm |
| 2018-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418020002/0001144204-18-020002-index.htm |
| 2018-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000114420418020005/0001144204-18-020005-index.htm |
| 2018-12-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/320017/000114420418063631/0001144204-18-063631-index.htm |
| 2019-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000119262119000010/0001192621-19-000010-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000119262119000013/0001192621-19-000013-index.htm |
| 2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000119262120000002/0001192621-20-000002-index.htm |
| 2020-07-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/320017/000121465920006425/0001214659-20-006425-index.htm |
| 2019-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000128450019000006/0001284500-19-000006-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000128450019000009/0001284500-19-000009-index.htm |
| 2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000128450020000002/0001284500-20-000002-index.htm |
| 2019-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000133454919000008/0001334549-19-000008-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000133454919000011/0001334549-19-000011-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000133454920000003/0001334549-20-000003-index.htm |
| 2020-01-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000133454920000005/0001334549-20-000005-index.htm |
| 2019-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000137358519000010/0001373585-19-000010-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000137358519000013/0001373585-19-000013-index.htm |
| 2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000137358520000002/0001373585-20-000002-index.htm |
| 2019-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000152454719000006/0001524547-19-000006-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000152454719000009/0001524547-19-000009-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000152454720000003/0001524547-20-000003-index.htm |
| 2020-01-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000152454720000005/0001524547-20-000005-index.htm |
| 2020-08-12 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000157378520000013/0001573785-20-000013-index.htm |
| 2020-08-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000157378520000014/0001573785-20-000014-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000157378520000017/0001573785-20-000017-index.htm |
| 2019-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000158381019000005/0001583810-19-000005-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000158381019000008/0001583810-19-000008-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000158381020000003/0001583810-20-000003-index.htm |
| 2020-01-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000158381020000006/0001583810-20-000006-index.htm |
| 2018-11-08 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000174145518000012/0001741455-18-000012-index.htm |
| 2018-11-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000174145518000014/0001741455-18-000014-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000174145519000003/0001741455-19-000003-index.htm |
| 2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/320017/000174145520000002/0001741455-20-000002-index.htm |
| 2017-09-19 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/320017/999999999517002400/9999999995-17-002400-index.htm |
| 2018-08-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/320017/999999999518001991/9999999995-18-001991-index.htm |
| 2020-06-29 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/320017/999999999520001584/9999999995-20-001584-index.htm |
| 2020-08-27 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/320017/999999999520002286/9999999995-20-002286-index.htm |
Caladrius Biosciences, Inc (CLBS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Caladrius Biosciences, Inc (CLBS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1218%Institutional Ownership: 1923%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-06-20 | DOUGLAS W LOSORDO | Officer | Buy | 13,300.00 | 8.64 | 114,912.00 | 100,389.00 | https://www.sec.gov/Archives/edgar/data/320017/000032001718000076/0000320017-18-000076-index.htm |
| 2020-09-09 | Michael H. Davidson | Director | Buy | 55,525.00 | 1.80 | 99,945.00 | 106,588.00 | https://www.sec.gov/Archives/edgar/data/320017/000157378520000017/0001573785-20-000017-index.htm |
| 2019-01-14 | DOUGLAS W LOSORDO | Officer | Buy | 16,000.00 | 113,753.00 | https://www.sec.gov/Archives/edgar/data/320017/000158381019000008/0001583810-19-000008-index.htm | ||
| 2018-06-20 | David J Mazzo | Chief Executive Officer | Buy | 33,300.00 | 8.64 | 287,712.00 | 125,544.00 | https://www.sec.gov/Archives/edgar/data/320017/000032001718000074/0000320017-18-000074-index.htm |
| 2020-01-13 | DOUGLAS W LOSORDO | Officer | Buy | 19,000.00 | 135,197.00 | https://www.sec.gov/Archives/edgar/data/320017/000158381020000006/0001583810-20-000006-index.htm | ||
| 2019-01-08 | GREGORY B BROWN | Director | Buy | 8,747.00 | 15,462.00 | https://www.sec.gov/Archives/edgar/data/320017/000137358519000010/0001373585-19-000010-index.htm | ||
| 2019-01-08 | PETER G TRABER | Director | Buy | 8,747.00 | 15,612.00 | https://www.sec.gov/Archives/edgar/data/320017/000128450019000006/0001284500-19-000006-index.htm | ||
| 2019-01-14 | David J Mazzo | Chief Executive Officer | Buy | 47,000.00 | 157,706.00 | https://www.sec.gov/Archives/edgar/data/320017/000133454919000011/0001334549-19-000011-index.htm | ||
| 2019-01-08 | STEVEN M KLOSK | Director | Buy | 8,747.00 | 17,812.00 | https://www.sec.gov/Archives/edgar/data/320017/000119262119000010/0001192621-19-000010-index.htm | ||
| 2020-01-13 | David J Mazzo | Chief Executive Officer | Buy | 46,000.00 | 199,010.00 | https://www.sec.gov/Archives/edgar/data/320017/000133454920000005/0001334549-20-000005-index.htm | ||
| 2019-01-14 | Cynthia Schwalm | Director | Buy | 12,121.00 | 4.95 | 59,998.95 | 24,390.00 | https://www.sec.gov/Archives/edgar/data/320017/000174145519000003/0001741455-19-000003-index.htm |
| 2019-01-14 | GREGORY B BROWN | Director | Buy | 12,121.00 | 4.95 | 59,998.95 | 27,583.00 | https://www.sec.gov/Archives/edgar/data/320017/000137358519000013/0001373585-19-000013-index.htm |
| 2019-01-14 | PETER G TRABER | Director | Buy | 12,121.00 | 4.95 | 59,998.95 | 27,733.00 | https://www.sec.gov/Archives/edgar/data/320017/000128450019000009/0001284500-19-000009-index.htm |
| 2019-01-14 | STEVEN M KLOSK | Director | Buy | 12,121.00 | 4.95 | 59,998.95 | 29,933.00 | https://www.sec.gov/Archives/edgar/data/320017/000119262119000013/0001192621-19-000013-index.htm |
| 2018-01-08 | Joseph Talamo | SVP and CFO | Buy | 13,300.00 | 30,120.00 | https://www.sec.gov/Archives/edgar/data/320017/000114420418001703/0001144204-18-001703-index.htm | ||
| 2018-06-20 | Joseph Talamo | SVP and CFO | Buy | 13,300.00 | 8.64 | 114,912.00 | 41,617.00 | https://www.sec.gov/Archives/edgar/data/320017/000032001718000078/0000320017-18-000078-index.htm |
| 2020-01-13 | Cynthia Schwalm | Director | Buy | 18,292.00 | 3.28 | 59,997.76 | 42,682.00 | https://www.sec.gov/Archives/edgar/data/320017/000174145520000002/0001741455-20-000002-index.htm |
| 2019-01-08 | STEVEN S MYERS | Director | Buy | 8,747.00 | 44,906.00 | https://www.sec.gov/Archives/edgar/data/320017/000107827419000006/0001078274-19-000006-index.htm | ||
| 2020-01-13 | GREGORY B BROWN | Director | Buy | 18,292.00 | 3.28 | 59,997.76 | 45,875.00 | https://www.sec.gov/Archives/edgar/data/320017/000137358520000002/0001373585-20-000002-index.htm |
| 2020-01-13 | PETER G TRABER | Director | Buy | 18,292.00 | 3.28 | 59,997.76 | 46,025.00 | https://www.sec.gov/Archives/edgar/data/320017/000128450020000002/0001284500-20-000002-index.htm |
| 2020-01-13 | STEVEN M KLOSK | Director | Buy | 18,292.00 | 3.28 | 59,997.76 | 48,225.00 | https://www.sec.gov/Archives/edgar/data/320017/000119262120000002/0001192621-20-000002-index.htm |
| 2019-01-14 | Joseph Talamo | SVP and CFO | Buy | 16,000.00 | 49,415.00 | https://www.sec.gov/Archives/edgar/data/320017/000152454719000009/0001524547-19-000009-index.htm | ||
| 2019-01-14 | STEVEN S MYERS | Director | Buy | 12,121.00 | 4.95 | 59,998.95 | 57,027.00 | https://www.sec.gov/Archives/edgar/data/320017/000107827419000009/0001078274-19-000009-index.htm |
| 2020-01-13 | Joseph Talamo | SVP and CFO | Buy | 19,000.00 | 64,435.00 | https://www.sec.gov/Archives/edgar/data/320017/000152454720000005/0001524547-20-000005-index.htm | ||
| 2017-11-01 | DOUGLAS W LOSORDO | Officer | Buy | 49,182.00 | 68,876.00 | https://www.sec.gov/Archives/edgar/data/320017/000114420417055543/0001144204-17-055543-index.htm | ||
| 2020-01-13 | STEVEN S MYERS | Director | Buy | 18,292.00 | 3.28 | 59,997.76 | 75,319.00 | https://www.sec.gov/Archives/edgar/data/320017/000107827420000002/0001078274-20-000002-index.htm |
| 2020-11-01 | Anne Clem Whitaker | Director | Buy | 79,470.00 | 1.51 | 119,999.70 | 79,470.00 | https://www.sec.gov/Archives/edgar/data/320017/000110465920121061/0001104659-20-121061-index.htm |
| 2018-01-08 | DOUGLAS W LOSORDO | Officer | Buy | 13,300.00 | 88,892.00 | https://www.sec.gov/Archives/edgar/data/320017/000114420418001705/0001144204-18-001705-index.htm | ||
| 2018-01-08 | David J Mazzo | Chief Executive Officer | Buy | 33,300.00 | 96,706.00 | https://www.sec.gov/Archives/edgar/data/320017/000114420418001704/0001144204-18-001704-index.htm |